ORCHARD THERAPEUTICS (FRANCE) SAS : revenue, balance sheet and financial ratios

ORCHARD THERAPEUTICS (FRANCE) SAS is a French company founded 6 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in PARIS (75001), this company of category PME shows in 2024 a revenue of 5.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - ORCHARD THERAPEUTICS (FRANCE) SAS (SIREN 879573194)
Indicator 2024 2023 2022 2021 2020
Revenue 4 973 209 € 4 049 682 € 3 844 982 € 2 401 722 € 975 984 €
Net income 111 595 € 150 534 € 237 384 € 46 830 € -224 679 €
EBITDA 242 047 € 213 608 € 258 574 € 62 815 € -352 520 €
Net margin 2.2% 3.7% 6.2% 1.9% -23.0%

Revenue and income statement

In 2024, ORCHARD THERAPEUTICS (FRANCE) SAS achieves revenue of 5.0 M€. Over the period 2020-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +50.2%. Vs 2023, growth of +23% (4.0 M€ -> 5.0 M€). After deducting consumption (0 €), gross margin stands at 5.0 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 242 k€, representing 4.9% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 112 k€, i.e. 2.2% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

4 973 209 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

4 973 209 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

242 047 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

241 343 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

111 595 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

4.9%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 672%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 7%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 10.2 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 4.3% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

672.339%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

6.626%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

4.281%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

10.159

Solvency indicators evolution
ORCHARD THERAPEUTICS (FRANCE) SAS

Sector positioning

Debt ratio
672.34 2024
2022
2023
2024
Q1: 0.0
Med: 4.27
Q3: 43.96
Watch +51 pts over 3 years

In 2024, the debt ratio of ORCHARD THERAPEUTICS (FRA... (672.34) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
6.63% 2024
2022
2023
2024
Q1: 14.64%
Med: 38.36%
Q3: 60.56%
Average

In 2024, the financial autonomy of ORCHARD THERAPEUTICS (FRA... (6.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
10.16 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.0 years
Q3: 1.09 years
Watch +50 pts over 3 years

In 2024, the repayment capacity of ORCHARD THERAPEUTICS (FRA... (10.16) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 209.56. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 41.9x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

209.562

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

41.853

Liquidity indicators evolution
ORCHARD THERAPEUTICS (FRANCE) SAS

Sector positioning

Liquidity ratio
209.56 2024
2022
2023
2024
Q1: 132.74
Med: 202.27
Q3: 325.9
Good +32 pts over 3 years

In 2024, the liquidity ratio of ORCHARD THERAPEUTICS (FRA... (209.56) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Interest coverage
41.85x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.41x
Q3: 6.25x
Excellent +24 pts over 3 years

In 2024, the interest coverage of ORCHARD THERAPEUTICS (FRA... (41.9x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 150 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 84 days. The gap of 66 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 116 days of revenue, i.e. 1.6 M€ to permanently finance. Over 2020-2024, WCR increased by +1067%, requiring additional financing.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

1 602 418 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

150 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

84 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

116 j

WCR and payment terms evolution
ORCHARD THERAPEUTICS (FRANCE) SAS

Positioning of ORCHARD THERAPEUTICS (FRANCE) SAS in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of ORCHARD THERAPEUTICS (FRANCE) SAS is estimated at 421 271 € (range 219 557€ - 1 339 476€). With an EBITDA of 242 047€, the sector multiple of 0.7x is applied. The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
124 transactions
219k€ 421k€ 1339k€
421 271 € Range: 219 557€ - 1 339 476€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
242 047 € × 0.7x
Estimation 170 373 €
80 542€ - 620 097€
Revenue Multiple 30%
4 973 209 € × 0.21x
Estimation 1 059 166 €
574 361€ - 3 208 232€
Net Income Multiple 20%
111 595 € × 0.8x
Estimation 91 677 €
34 893€ - 334 793€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare ORCHARD THERAPEUTICS (FRANCE) SAS with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about ORCHARD THERAPEUTICS (FRANCE) SAS

What is the revenue of ORCHARD THERAPEUTICS (FRANCE) SAS ?

The revenue of ORCHARD THERAPEUTICS (FRANCE) SAS in 2024 is 5.0 M€.

Is ORCHARD THERAPEUTICS (FRANCE) SAS profitable?

Yes, ORCHARD THERAPEUTICS (FRANCE) SAS generated a net profit of 112 k€ in 2024.

Where is the headquarters of ORCHARD THERAPEUTICS (FRANCE) SAS ?

The headquarters of ORCHARD THERAPEUTICS (FRANCE) SAS is located in PARIS (75001), in the department Paris.

Where to find the tax return of ORCHARD THERAPEUTICS (FRANCE) SAS ?

The tax return of ORCHARD THERAPEUTICS (FRANCE) SAS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does ORCHARD THERAPEUTICS (FRANCE) SAS operate?

ORCHARD THERAPEUTICS (FRANCE) SAS operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.